The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Ferulic acid attenuates liver fibrosis and hepatic stellate cell activation via inhibition of TGF-β/Smad signaling pathway
Open accessAbstract
PURPOSE: Liver fibrosis is a worldwide health issue. Development of effective new drugs for treatment of this disease is of great importance. This study investigated the therapeutic effects of ferulic acid on liver fibrosis in vitro and in vivo. MATERIALS AND METHODS: Human hepatic stellate cell line (HSC) LX-2 was used for in vitro assays. Transforming growth factor β1 (TGF-β1) was used to induce hepatic fibrosis in LX-2 cells. Western blot was used to detect protein levels of collagen I, fibronectin, α-smooth muscle actin (SMA), p-Smad2, p-Smad3, p-p38, and p-JNK. Gene expression was measured by RT-qPCR. Fluorescence staining was used to determine localization of Smad4. CCl4-induced hepatic fibrosis in SD rats was used as an in vivo model. Histological features were detected by hematoxylin and eosin staining. Levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), hexadecenoic acid (HA), and hydroxyproline (Hyp) were measured by ELISA. RESULTS: TGF-β1 treatment significantly increased levels of collagen I, fibronectin, α-SMA, p-Smad2, p-Smad3, and Smad4 in LX-2 cells. Ferulic acid improved TGF-β1-induced hepatic fibrosis via regulation of the TGF-β1/Smad pathway. Consistent with in vitro data, CCl4 caused severe hepatic fibrosis in SD rats, as determined by ALT, AST, HA, and Hyp upregulation. Protein levels of p-Smad2 and p-Smad3 in liver tissues were significantly increased following treatment with CCl4. All CCL4-induced changes were markedly attenuated by ferulic acid treatment. CONCLUSION: Ferulic acid potently improved hepatic fibrosis via inhibition of the TGF-β1/Smad pathway in vitro and in vivo. These findings provided evidence for potential use of ferulic acid to treat or prevent liver fibrosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liver fibrosis – from bench to bedside
Friedman, S. L. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00429-4 · Cited by 1,780
Hepatic fibrosis: molecular mechanisms and drug targets
Lotersztajn, S., Julien, B., Teixeira-Clerc, F., Grenard, P., & Mallat, A. (2005) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.45.120403.095906 · Cited by 325
Reversibility of liver fibrosis
Pellicoro, A., Ramachandran, P., & Iredale, J. P. (2012) · Fibrogenesis & Tissue Repair · doi:10.1186/1755-1536-5-s1-s26 · Cited by 135
Cited by
Antar, S. A., Ashour, N. A., Marawan, M. E., & Al-Karmalawy, A. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24044004 · Cited by 366
Liver fibrosis resolution: from molecular mechanisms to therapeutic opportunities
Pei, Q., Yi, Q., & Tang, L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119671 · Cited by 121
Du, Z., Wu, T., Liu, L., Luo, B., & Wei, C. (2022) · Digestive and Liver Disease · doi:10.1016/j.dld.2021.02.025 · Cited by 13
Zhang, R., Li, W., Jiang, X., Cui, X., You, H., Tang, Z., & Liu, W. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.863797 · Cited by 9
Jung, H., Kyun, M.-L., Kwon, J.-I., Kim, J., Kim, J.-K., Park, D., Lee, Y. B., & Moon, K.-S. (2024) · Biomaterials Science · doi:10.1039/d4bm00874j · Cited by 10
Metadata
- Authors
- Mu, M., Zuo, S., Wu, R.-M., Deng, K.-S., Lu, S., Zhu, J.-J., Zou, G.-L., Yang, J., Cheng, M.-L., & Zhao, X.-K.
- Venue
- Drug Design, Development and Therapy
- Publisher
- Informa UK Limited
- Published
- 2018-12
- Volume
- Volume 12
- Pages
- 4107-4115
- ISSN
- 1177-8881 (ISSN-L)
- OpenAlex
- W2902937135
- Cited by
- 186
- References
- 3
- FWCI
- 5.47
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ferulic acid attenuates liver fibrosis and hepatic stellate cell activation via inhibition of TGF-β/Smad signaling pathway. https://app.cochat.ai/papers/10.2147/dddt.s186726
- The paper
- Mu, M., Zuo, S., Wu, R.-M., Deng, K.-S., Lu, S., Zhu, J.-J., Zou, G.-L., Yang, J., Cheng, M.-L., & Zhao, X.-K. (2018). Ferulic acid attenuates liver fibrosis and hepatic stellate cell activation via inhibition of TGF-β/Smad signaling pathway. Drug Design, Development and Therapy. https://doi.org/10.2147/dddt.s186726
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.